Fig. 3.

Some but not all HNSCC cell lines are growth-dependent on EGFR overexpression and activity. a, high EGFR-expressing cells respond more strongly to lapatinib treatment than low EGFR-expressing cells. b, signaling pathway analysis using phospho-specific antibodies reveals that lapatinib treatment inhibits the EGFR/AKT and EGFR/ERK pathways. c, high EGFR-expressing cells respond more strongly to siRNA-mediated EGFR knockdown than low EGFR-expressing cells. d, Western blot analysis documenting EGFR knockdown efficiency in CAL27, UPCISCC056, and UTSCC87 cells.